Analgesic Efficacy of Adding Sciatic Blockade to the 3-in-1 Block Following Total Knee Arthroplasty: A Meta-analysis
Abstract
Background: Total knee arthroplasty (TKA) is one of the most common orthopedic procedures performed. It is also invasive and is associated with severe postoperative pain. The 3-in-1 block has been repeatedly demonstrated to provide effective postoperative analgesia. However, adding sciatic blockade to the 3-in-1 has become a growing practice as a result of residual pain to the posterior knee, although the additional benefit is unknown particularly in light of the potential risks. Purpose: To examine the analgesic efficacy and associated adverse events of adding sciatic blockade to the 3-in-1 block compared to the 3-in-1 alone for postoperative analgesia following TKA. Methods: A meta-analysis was conducted on relevant articles from 1993 to 2010. Methodological rigor was applied to each of the analytical procedures including: evaluation of between-study heterogeneity, pooling effects, subgroup analyses, sensitivity analysis, and assessment of publication bias. Results: Nine studies representing 1827 subjects were included. Pain outcomes were measured with the visual analog scale both at rest (VASr) and dynamic (VASd) and reported as the weighted mean difference (WMD). The addition of sciatic blockade demonstrated improved postoperative analgesia with the greatest effects up to 24 hours postoperatively: early (6-8hr) VASr WMD -2.039 (95% CI: -2.718, -1.360); 12hr VASr WMD -1.491 (95% CI: -2.174, -0.808); 24hr VASr WMD -0.767 (95% CI: -1.114, -0.421); 24hr VASd WMD -0.671 (95% CI: -1.301, -0.041). The 24hr opioid consumption was also lower [WMD -10.237 (95% CI: -20.029, -0.444)]. After 24 hours, effects were small and/or not significant. There was also a statistically significant advantage in maximum knee flexion on POD3 [WMD -7.102 (95% CI: -11.864, -2.339)]. A lack of consistent reporting precluded quantitative analysis on adverse events. Conclusion: Findings support the use of peripheral nerve blocks for postoperative analgesia following TKA. The addition of sciatic blockade appears to offer greater analgesic efficacy than a 3-in-1 block alone but only in the early postoperative period. However, until an accurate estimate of associated adverse events can be unveiled, the addition of a sciatic block cannot be recommended for all patients following TKA. It should, however, be considered in the postoperative period for those patients who continue to experience substantial pain to the posterior aspect of the knee on a case-by-case basis.Description
University of Maryland, Baltimore. Nursing. Ph.D. 2010Keyword
3-in-1 nerve blockfemoral nerve block
peripheral nerve block
postoperative analgesia
sciatic nerve block
total knee arthroplasty
Arthroplasty, Replacement, Knee
Nerve Block
Pain, Postoperative
Identifier to cite or link to this item
http://hdl.handle.net/10713/894Related items
Showing items related by title, author, creator and subject.
-
Mechanisms of Action and Efficacy Modulation of Novel Retinoic Acid Metabolism Blocking Agent (RAMBA) VN/12-1 in Estrogen Receptor-α Negative Breast Cancer Model Systems: Targeting AutophagyGodbole, Abhijit Moreshwar; Njar, Vincent (2011)Breast cancer (BC) is the most common cancer and the second leading cause of cancer related deaths among women in the United States. Despite important advances in treatment, breast cancer remains incurable due to the emergence of alternative pathways adopted by cancer cells to overcome the effects of anti-cancer therapy. This molecular heterogeneity in the cellular response to anti-cancer therapy challenges the development of effective therapeutic strategies. To overcome this issue, a rational approach would be to concomitantly target clinically relevant cellular abnormalities with combination therapy or to use a potent multi-targeted agent. Autophagy is a critical physiological process of cancer cell survival in the presence of chemotherapeutic stress and is an important cause of resistance to anti-cancer therapy. Drugs that inhibit autophagy e.g. chloroquine-(CHL) deprive the cells of this protective mechanism and therefore are promising agents in combination chemotherapy of breast cancer. All-trans retinoic acid (ATRA), a potent differentiation inducing agent, has been tested as anticancer agent for a number of cancers including breast cancer, but its rapid metabolism to inactive metabolites is a major problem in its clinical use. VN/12-1, a novel retinoic acid metabolism blocking agent (RAMBA) developed in our laboratory, showed improved anti-proliferative activity over ATRA against estrogen receptor α (ER-α) positive and negative breast cancer cell lines. Human epidermal growth factor receptor-2 (Her-2) is a critical protein involved cell proliferation and metastasis. Her-2 has been involved in increasing the frequency of tumor stem cells and it has also been implicated in the development of drug resistance. Hence, for our current studies, we primarily focused on a cell line which is deficient in ER-α and which overexpresses Her-2 (SKBR-3 cells). We showed here that VN/12-1 inhibits G1-S phase cell cycle transition. However, short treatment of VN/12-1 induced autophagy in these cells and protected cells from apoptosis. VN/12-1-induced autophagy was preceded by ER stress (ERS). We further demonstrated that suppression of autophagy using either pharmacological inhibitors or RNA interference of Beclin-1 enhanced cell death induced by VN/12-1 in SKBR-3 cells. The combination of VN/12-1with autophagy inhibitor - CHL resulted in synergistic effects in that it enhanced apoptosis in vitro and in vivo which was caspase dependent. Importantly, VN/12-1 (5 mg/kg twice weekly) and VN/12-1 (5 mg/kg twice weekly) + chloroquine (50 mg/kg twice weekly) significantly suppressed established SKBR-3 tumor growth by 81.4% (p < 0.001 vs. control) and 96.2% (p < 0.001 vs control), respectively without incurring overt signs of toxicity or significant loss of body weight. Together, these findings suggest that autophagy inhibitors may enhance the therapeutic effects of RAMBAs in the treatment of breast cancer. It is hoped that this combination therapy would solve the problem of the development of acquired resistance due to autophagy that typically follows the chemotherapeutic treatment of breast cancer. We envision further advanced preclinical development of this combination therapy as potential therapy for breast cancer.
-
Think Inside the Blocks: Health Literacy Outreach to Disadvantaged People in Their Own EnvironmentPatterson, Nancy; Pinkas, Maria M. (2011-08)This is a bilingual poster with parallel content in English and Spanish. It presents places in the community where health literacy outreach can take place: the school (la escuela), the church (la iglesia), the local library branch (la biblioteca publica de la comunidad), public housing computer centers (centros de computadoras en residenciales publicos), the home (el hogar), the beauty salon (el salon de belleza).
-
Inhibition of the zonulin pathway blocks the progression from pre-clinical autoimmunity to Type 1 diabetes in BB/wor ratsFasano, Alessio (2005)Background: We have previously studied that zonulin, a protein involved in tight junctions modulation, is up regulated in BB/wor rats and is responsible for the increased intestinal permeability (IP) typical of this animal model of autoimmunity. We have also demonstrated that by blocking the zonulin pathway before the onset of autoimmunity, the incidence of Type 1 Diabetes (T1D) can be prevented in 75% of the animals. Aim : To determine whether the progression of T1D can be blocked, even though the autoimmune process is already established. Methods: 30 BB/ Wor rats were randomized after immune seroconversion (average age 55 days) in a treatment group (N=20) that received autoclaved water supplemented with 3mg /ml of zonulin receptor blocker AT1001 and HCO3- 1.5g/100ml to buffer gastric acidity, and a placebo group (N=10) that received only water with HCO3-. Serum zonulin and autoantibody levels were monitored at the beginning of the study and at its endpoint. Water intake was monitored daily, weight gain and serum glucose levels were checked weekly. Rats with fasting blood glucose 250 mg/dl were considered diabetic and were sacrificed within 24 hours of reaching the diabetic status. Results: Six out of 10 (60%) untreated rats developed T1D, while only 7/20 (35%) of the AT1001-treated animal progressed to T1D. The average age of onset of T1D was 85.410.4 in the placebo group and 86.010.3 in the treated group. AT1001 treatment did not change the serum zonulin levels between beginning (average age 55 days) and the endpoint of the experiment (average age 100 days) of the experiments. Conversely, the anti-glutamic acid decarboxylase (GAD) antibodies were significantly reduced in AT1001-treated rats that did not develop T1D (0.870.35) compared to the treated animals with the disease developed (1.870.59; p<0.05) Conclusions: The blockage of the zonulin pathway in BB/wor rats at their preclinical autoimmune stage significantly reduced the progression to T1D. This decreased incidence of T1D was associated to a significant reduction of the anti-GAD antibodies following AT1001 treatment.